The FINANCIAL - Health & Beauty

The FINANCIAL -- NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. and Astellas Pharma Inc.  announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completion dates of both ...

The FINANCIAL -- The U.S. Food and Drug Administration (FDA) recently finalized guidance to help biopharmaceutical manufacturers communicate about their products with payers, to support value-based ...

The FINANCIAL -- William T. Reynolds, O.D., specializes in caring for patients calls "mature" at private group practice in Richmond, Kentucky. On average, the patients range in age from 45 to 75, ...

The FINANCIAL -- Boston, MA – People who gain weight after they quit smoking may face a temporary increase in the risk of developing type 2 diabetes, with the risk directly proportional to the ...

The FINANCIAL -- ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of ...